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Regulation of both the expression and function of con-
nexins in the vascular wall is important during athero-
sclerosis. Progression of the disease state is marked by
vascular smooth muscle cell (VSMC) proliferation,
which coincides with the reduced expression levels of
connexin 43 (Cx43). However, nothing is currently
known about the factors that regulate post-translational
modifications of Cx43 in atherogenesis, which could be
of particular importance, due to the association be-
tween site-specific Cx43 phosphorylation and cellular
proliferation. We compared the effects of direct carotid
applications of two oxidized phospholipid derivatives,
1-palmitoyl-2-oxovaleroyl-sn-glycero-3-phosphorylcho-
line (POVPC) and 1-palmitoyl-2-glutaroyl-sn-glycero-3-
phosphorylcholine (PGPC), on Cx43 expression and
phosphorylation, and on cell proliferation. Since both
POVPC and PGPC have been shown to act through
different intracellular pathways, we hypothesized
that each oxidized phospholipid species could induce
differential Cx43 phosphorylation events in the cyto-
plasmically located carboxyl-terminal region of the pro-
tein, which could potentially enhance cell proliferation.
Application of POVPC caused a reduction in VSMC Cx43
levels, enhanced its phosphorylation at serine (pS) 279/
282, and increased VSMC proliferation both in vivo
and in vitro. Treatment with PGPC enhanced VSMC
pS368 levels with no associated change in prolifer-
ation. These oxidized phospholipid-induced Cx43
post-translational changes in VSMCs were consistent
with those identified in ApoE/ mice. Taken to-
gether, these results demonstrate that post-transla-
tional phosphorylation of Cx43 could be a key factor
in the pathogenesis of atherosclerosis. (Am J Pathol
2009, 175:916–924; DOI: 10.2353/ajpath.2009.090160)
One of the markers of atherogenesis is a change in con-
nexin 43 (Cx43) protein expression in the vascular smooth
muscle cells (VSMCs) of the large vessels.1–3 Reductions in
VSMC Cx43 protein expression and functionality has been
associated with enhanced VSMC proliferation and differen-
tiation, which is a central component of atherogenic pro-
gression.1,4 Connexin 43 expression and functionality is
controlled in a large part through post-translational phos-
phorylation of sites within its cytoplasmically located car-
boxyl terminal region. Differential phosphorylation events of
the Cx43 carboxyl terminus can influence Cx protein ex-
pression,5 targeting,6 function,3,7 and may act to control
cellular proliferation.3,8,9 Post-translational modifications of
Cx43 may therefore be integral to cell cycle progression in
VSMCs. However, no evidence exists that Cx43 is phos-
phorylated in VSMCs during atherogenic progression.
During atherogenesis, minimally modified low den-
sity lipoproteins, the oxidative products of low-density
lipoprotein, accumulate in vessel walls.10 Oxidized phos-
pholipids (OxPLs), active components in minimally mod-
ified low density lipoproteins, have been identified as a
major contributing factor in pro-atherogenic events, en-
hancing further lipid accumulation and oxidation, and are
thought to promote key changes in VSMC phenotype,
triggering the disease state.11 Several biologically active
derivatives of minimally modified low density lipoprotein, eg,
oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phos-
phorylcholine (OxPAPC), as well as its component lipids,
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phorylcholine (POVPC), have been identified as critical
markers of atherosclerotic progression.12 In clinical stud-
ies, administration of lipid-lowering drugs reduces cell
proliferation,13 and POVPC and PGPC identified in fatty
streak lesions are associated with increased proliferation
of the VSMC in vitro.14–16 It is unclear how POVPC and
PGPC promote these alterations, but these lipids have
been shown to have differing biological activities, pro-
moting activation of mitogen-activated protein kinase
(MAPK) and protein kinase C (PKC) cascades respec-
tively.14,17 The differential activation of signaling cas-
cades by these OxPL species implicates a possible path-
way in which they could individually mediate Cx43’s
functionality through carboxyl terminus phosphorylation.
Kinase mediated phosphorylation of Cx43 carboxyl ter-
minus sites through MAPK (eg, phosphorylation at serine
(pS) 279/282) and PKC (eg, pS368) have been shown to
reduce Cx43 functionality, channel docking, and affect
cell proliferation rates.18,19
In this study, we tested the hypothesis that POVPC
and PGPC differentially mediate Cx43 phosphorylation
and induce changes in the proliferative state of VSMC
in vivo and in vitro. Following application directly to
carotid arteries, POVPC and PGPC mediated site-spe-
cific Cx43 phosphorylation at pS279/282 and pS368
respectively. Applications of POVPC caused reduc-
tions in total Cx43 (Cx43-T) and enhanced pS279/282,
which corresponded to an increase in VSMC prolifer-
ation in vivo and in vitro. While PGPC enhanced pS368,
no changes in VSMC proliferation were observed. In
keeping with these findings, Cx43 was phosphorylated
at the pS279/282 and pS368 sites in ApoE/ mice, but
not in wild-type mice. These changes implicate key
roles for both POVPC and PGPC in the specific post-
translational modifications of Cx43 and as possible
initiating factors and markers of early atherogenic
changes in the vessel wall.
Materials and Methods
Mice
All C57/Bl6 mice (Taconic) used for pluronic applica-
tions were 6- to 8-week-old males. For comparisons of
Cx43 expression and phosphorylation in atheroscle-
rotic mice, 15-week-old ApoE/ mice (Jackson labs)
and age-matched C57/BL6 (Taconic) mice were used.
All mice were kept on a standard 12-hour light/dark
cycle and fed a normal chow diet. Food and water was
available ad libitum. All animals were used according
to the University of Virginia Animal Care and Use Com-
mittee guidelines.
Carotid Surgeries
Surgeries were performed as described20; briefly, mice
were anesthetized with an i.p. injection of ketamine-xyla-
zine, the left common carotid artery exposed, and PGPC
or POVPC was topically applied (mixed in pluronic gel,
F-127) at the stated dosages to the outside of the carotid
wall. As shown in Figure 1A, application of the lipids in
F-127 permits specific localization to the carotids. Twen-
ty-four hours after the surgery, mice were euthanized with
an i.p. injection of 60 to 90 mg/kg pentobarbital, and the
carotids were placed in liquid N2-cooled 4-methyl butane
and transferred to optimal cutting temperature com-
pound for frozen sectioning or fixed in 4% paraformalde-
hyde for whole-mount analysis.
Antibodies
Immunocytochemistry and Western blot analysis of sam-
ples were performed using antibodies for rabbit polyclonal
Cx43, which recognizes Cx43 in its phosphorylated and
non-phosphorylated states (Cx43-T, Sigma21), rabbit anti-
Cx43 pS279/282 (pS279/28219), rabbit anti-Cx43 pS368
(pS368) obtained from Cell Signaling technologies (as ver-
ified19), mouse anti-Cx37 ( diagnostics22), mouse anti-
Cx40 ( diagnostics22) rabbit anti-Cx45 (Kind gift T.H.
Steinberg23), and monoclonal -tubulin (Sigma). Anti-
bodies were visualized with donkey anti-rabbit Alexa 594
for immunocytochemistry or using 680/800 nm conjugated
secondary antibodies (LI-COR) for Western blotting.
Immunocytochemistry
Immunocytochemistry on mouse carotids treated with ox-
idized phospholipid species was performed as de-
scribed.20 Images of single antibody stains to be used for
quantification were obtained on an Olympus FV200 con-
focal microscope (objective 60 0.9 NA) with intensity
and exposure settings held constant for each antibody
tested. For quantification of pixel intensities in carotids,
10 m  20 m boxes were placed between layers of
elastic lamina in the VSMC layers (as described24). In
each image, at least three areas of VSMC were re-
corded; at least three images were used per mouse
per treatment (n  3).
Transmission Electron Microscopy
Carotids were placed in 4% paraformaldehyde and 2.5%
glutaraldehyde overnight at 4°C. Transmission electron
microscopy processing was performed by post-fixing
with 1% osmium tetroxide, followed by dehydration in a
gradient of alcohols and embedded in Epon. Thin sec-
tions (approximately 75 nm) were cut and carbon
coated and imaged on a Joel 1230 transmission elec-
tron microscope.
Cell Culture
Primary cultures of rat aortic smooth muscle cells (ASMC,
kind gift G. K. Owens, see supplemental Figure S1 at
http://ajp.amjpathol.org, as described25) were grown in
Dulbecco’s Modified Eagles Medium-F12 containing
10% fetal bovine serum, L-glutamine (1.6 mmol/L), peni-
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cillin (100 units/ml), and streptomycin (100 g/ml). To
induce a quiescent phenotype, cells were incubated for
48 hours in insulin-free, serum-free Dulbecco’s Modified
Eagles Medium-F12 supplemented with L-ascorbic acid
(35 g/ml), apo-transferrin (5 g/ml), sodium selenite
(6.25 g/ml), L-glutatmine (1.6 mmol/L), penicillin (100
units/ml), and streptomycin (100 g/ml). Quiescence was
verified by flow cytometry (as described26). For positive
controls, quiescent cells were incubated with platelet-
derived growth factor (PDGF-BB 20 ng/ml) in insulin-free,
serum-free media for 24 hours.
In Vitro Cx Expression
Treated ASMC cells (75% to 80% confluent) were lysed in
20 mmol/L Tris-HCL plus Na3VO4 (500 mol/L), NaF (10
mmol/L), 4-(2-Aminoethyl) benzenesulfonyl fluoride hy-
drochloride (10 mol/L), 1 complete protease inhibitors
(Sigma), and phosphatase inhibitors (Sigma). Membrane
fractions were separated via centrifugation (100,000  g,
5 minutes, as described27). Membrane protein extracts
(15 g), were analyzed by Western blot (10% SDS),
transferred to nitrocellulose, probed for protein expres-
sion with primary antibodies (as described), and second-
ary antibody fluorescence was detected using a LI-COR
Odyssey infrared scanner. All fluorescence intensities
were normalized against -tubulin for loading.
VSMC Proliferation
Mice were pre-treated with an i.p. injection of the thymi-
dine analogue 5-ethynyl-2-deoxyuridine (EDU, 100 g,
Invitrogen) 48 hours before carotid application of the
OxPLs.28 Carotid surgeries were performed as described
above with control mice solely anesthetized with ket-
amine or with F-127 applications. Treated mice had
POVPC or PGPC (100 g) in F-127 applied to the left
common carotid artery. Twenty-four hours after the sur-
gery, mice were euthanized with an i.p. injection of 60 to
90 mg/kg pentobarbital and the carotids were removed.
Whole carotids fixed in 4% paraformaldehyde were
washed in PBS and permeabilized using 0.5% Triton
X-100, and incorporated EDU was conjugated to an Al-
exa Fluor 594-azide using the Click-IT reagent kit (Invitro-
gen). Following staining, carotids were cut laterally up the
vessel and washed overnight in PBS, and cell nuclei were
stained using Sytox green (488 nm, Invitrogen). Carotids
(n  4 for each treatment) were pinned open and visu-
alized by confocal (Olympus Fluoview) microscopy at
three randomized sections along the length of each ca-
rotid. Z-stack images, approximately 30 m, with approx-
imately 300 to 500 cells in view, were compressed to a
single file for counting. Total cells viewed were between
3500 to 4500 nuclei for each treatment. Positive EDU
incorporation was determined as previously described
for nuclear bromodeoxyuridine and EDU staining28,29
and confirmed in ligated carotids from control 6–8 week
C57/Bl6 mice (see supplemental Figure S2 at http://
ajp.amjpathol.org, as described30) and in small intestinal
epithelial cells (see supplemental Figure S3 at http://
ajp.amjpathol.org). We confirmed the specificity of local-
ization of this treatment by analysis of proliferation in the
aortic and mesenteric vessels from POVPC treated mice,
which were negative for proliferation (see supplemental
Figure S3 at http://ajp.amjpathol.org). The number of nu-
Figure 1. Expression of Cx43-T in carotid VSMC in vivo. The image sequence
in (A) is of an intact whole mouse on a LI-COR Odyssey imager. Pluronic gel
mixed with Alexa 633 (700 nm, red) was topically applied to a mouse carotid
for 24 hours before a tail-vein injection with a bolus of 800 nm conjugated
IgG to mark the vasculature (green). In image sequence (B–E), representa-
tive carotid images show Cx43-T expression in the carotid VSMC of DMPC
(B), ApoE/ (C), POVPC (D), and PGPC (E) mice. In (B–E), blue indicates
nuclei 4-6-Diamidino-2-phenylindole, green represents autofluorescence of
the elastic lamina, red indicates Cx43-T, and the asterisk indicates the
luminal side of the vessel. Scale bar  20 m (B), representative for (B–E).
In (F), the fluorescent intensities from secondary antibodies used to detect
Cx43-T were plotted according to different carotid experimental conditions:
15-week-old C57/Bl6 (control-15), 15-week-old ApoE/ mice fed a stan-
dard chow diet (ApoE/15), 6-week-old C57/Bl6 (control-6) mice with
only pluronic gel applied to the carotid (F-127), mice with 50 g DMPC
applied to the carotid (DMPC), mice with 10/50/100 g POVPC (10 POVPC/50
POVPC/100 POVPC respectively) applied to the carotid and mice with 10/50/
100g PGPC (10 PGPC/50 PGPC/100 PGPC) applied to carotid. In (F), #P 0.05
when compared with 6-week-old C57/Bl6, and *P 0.05 when compared with
6-week-old C57/Bl6 with 50 g DMPC applied to carotid.
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clei incorporating EDU was normalized against the total
nuclei in each image.
For in vitro studies using ASMC, quiescence was
induced and the cells (75% to 80% confluence) were
treated with a combination of EDU (20 g, as de-
scribed31) plus POVPC or PGPC (5 g/ml, as de-
scribed15) for 24 hours. Cells were prepared for flow
cytometry by fixation in 70% ethanol and permeabilized
using 0.1% Triton X-100, and EDU was conjugated to
Alexa Fluor 488-azide using the Click-IT reaction kit (In-
vitrogen). Negative control cells were incubated for a
total of 72 hours in insulin-free, serum-free media and
processed, as per the staining protocol, with and without
EDU for 24 hours, or with PDGF plus EDU for 24 hours as
positive controls. A total of 20,000 viable gated cells were
collected for each treatment (n  3, FACSCalibur BD
Biosciences). Positive and negative gates in the 488/
FL1-H channel (EDU positive) were based on the controls
(above) and applied to each sample using FloJo soft-
ware. Normalized percentages of positive cells were
compared with total cell numbers.
Statistics
Significance was determined compared with the relevant
controls (as described) using One-way analysis of vari-
ance (Bonferroni post hoc test) at significances of *P 
0.05 and ***P  0.001.
Results
POVPC but not PGPC Reduces Total VSMC
Cx43 Expression in Vivo
To investigate whether reductions in Cx43 during early
atherogenesis1 are associated with the presence of spe-
cific OxPLs, we examined total Cx43 (Cx43-T) levels in
mouse carotids under control and treated conditions. In
6- to 8-week C57/Bl6 mice, Cx43-T was shown to be
expressed in VSMC layers, which was not significantly
altered in anesthetic control mice, mice treated with ve-
hicle pluronic F-127, or mice treated with the control lipid
DMPC (Figure 1, B and F). In ApoE/ mice, Cx43-T
expression was reduced compared with age matched
C57/Bl6 mice (Figure 1, C and F). Applications of POVPC
to carotids produced significant, dose-dependent, re-
ductions in VSMC Cx43-T (Figure 1, D and F). However,
PGPC applied to carotids did not significantly alter the
expression of Cx43-T (Figure 1, E and F). To investigate
changes in other vascular connexins, we compared ex-
pression of Cx 37, 40, and 45 in control, OxPL-treated,
and in ApoE/ mice, and identified only elevated levels
of Cx37 in ApoE/ carotids (Figure 2, A–D). These data
implicate POVPC, but not PGPC, as causative in reduc-
ing Cx43-T in the VSMC of carotids, similar to levels
identified in carotids of ApoE/ mice.
POVPC and PGPC Differentially Phosphorylate
VSMC Cx43 in Vivo
Targeting, functionality, and expression of Cx43 are
highly regulated through phosphorylation at sites within
its carboxyl terminus,3–7 yet no data currently exist de-
scribing Cx43 phosphorylation in atherogenic states. In
all control mice, Cx43 was poorly phosphorylated at
pS279/282 in carotid VSMC, but levels were significantly
elevated in ApoE/ mice, as compared with age-
matched controls (Figure 3, A, B, E). Significant dose-
dependent increases in pS279/282 were observed in the
carotids of POVPC, but not PGPC-treated mice (Figure 3,
C–E). Low amounts of Cx43 pS368 were detectable in all
control mice, with elevated levels identified in ApoE/
mice, as compared with age-matched controls (Figure 4,
A, B, E). Applications of PGPC, but not POVPC enhanced
levels of Cx43 pS368, as compared with controls (Figure
4, C–E). These findings demonstrate that POVPC and
PGPC differentially phosphorylate Cx43 in vivo.
The presence of OxPLs has been linked with en-
hanced proliferation in vitro,14,15 similar reductions in
Cx43 expression and changes in its phosphorylation sta-
tus are thought to increase cell proliferation.3,18,32–35
Qualitative ultrastructural evaluations using transmission
Figure 2. Non-Cx43 vascular connexins expression in carotids. Images show
representative carotids from 6-week-old mice treated for 24 hours with (A)
DMPC (control), (C) POVPC (100 g) or (D) PGPC (100 g), and (B)
15-week ApoE/ mice. Carotids from mice were analyzed for connexin
expression by immunofluorescence using antibodies against mouse anti-
Cx37, mouse anti-Cx40, and rabbit anti-Cx45. In each image, blue represents
nuclei (DAPI), green represents autofluorescence of the elastic lamina, and red
represents Cx staining (as labeled). Scale bar  20 m in (A), representative for
all images; and the asterisk indicates the luminal side of the vessels.
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electron microscopy demonstrated, in control and PGPC-
treated mice, compact layers of VSMCs with normal,
regular-shaped nuclei, while in ApoE/ and POVPC-
treated mice, irregular-shaped, electron-dense nuclei in-
dicative of heterochromatic DNA and proliferative VSMCs
were identified (Figure 5A). These results demonstrate
that POVPC elicits signs of VSMC proliferation in treated
carotids.
POVPC but not PGPC Promotes Cell
Proliferation in Vivo
So as to quantitate our ultrastructural data, we next ex-
amined EDU uptake after lipid application. In anesthetic
and F-127 control mice, only 0.51%  0.27% and 0.41%
 0.24% (respectively) of all VSMC nuclei stained posi-
tive for EDU incorporation (Figure 5, B and D). The levels
Figure 3. Expression of Cx43-pS279/282 in carotid VSMC in vivo. In the
image sequence (A–D), representative carotid images show Cx43-pS279/282
expression in the VSMCs of DMPCs (A), ApoE/ (B), POVPC (C), and PGPC
(D) mice. In (A–D), blue indicates nuclei (DAPI), green represents autofluo-
rescence of the elastic lamina, red indicates pS279/282, and the asterisk
indicates the luminal side of the vessel. Scale bar 20 m (A); representative
for (A–D). In (E), the fluorescent intensities from secondary antibodies used
to detect Cx43-pS279/282 were plotted according to different carotid exper-
imental conditions: 15-week-old C57/Bl6 (control-15) mice, 15-week old-
ApoE/ mice fed a standard chow diet (ApoE/-15), 6-week-old C57/Bl6
(control-6) mice with only pluronics applied to the carotid (F-127), mice with
50 g DMPC applied to the carotid (DMPC), mice with 10/50/100 g POVPC
(10 POVPC/50 POVPC/100 POVPC respectively) applied to the carotid, and
mice with 10/50/100 g PGPC (10 PGPC/50 PGPC/100 PGPC) applied to
carotid. In (E), Pˆ 0.05, when compared with 15-week-old C57/Bl6 mice, #P
0.05, when compared with 6-week-old C57/Bl6 mice, and *P  0.05, when
compared with 6-week-old C57/Bl6, with 50 g DMPC applied to carotid.
Figure 4. Expression of Cx43-pS368 in carotid VSMCs in vivo. In the image
sequence (A–D), representative carotid images show Cx43-pS368 expression
in the VSMC of DMPC (A), ApoE/ (B), POVPC (C), and PGPC (D) mice. In
(A–D), blue indicates nuclei (DAPI), green represents autofluorescence of
the elastic lamina, red indicates pS368, and the asterisk indicates the luminal
side of the vessel. Scale bar  20 m in (A); representative for (A–D). In (E),
the fluorescent intensities from secondary antibodies used to detect Cx43-
pS368 were plotted according to different carotid experimental conditions:
15-week-old C57/Bl6 (control-15) mice, 15-week-old ApoE/ mice fed a
standard chow diet (ApoE/-15), 6-week-old C57/Bl6 (control-6) mice with
only pluronics applied to the carotid (F-127), mice with 50 g DMPC applied
to the carotid (DMPC), and mice with 10/50/100 g POVPC (10 POVPC/50
POVPC/100 POVPC respectively) applied to the carotid and mice with
10/50/100 g PGPC (10 PGPC/50 PGPC/100 PGPC) applied to the carotid. In
(E), #P  0.05, when compared with 6-week-old C57/Bl6, and *P  0.05,
when compared with 6-week-old C57/Bl6 with 50 g DMPC applied to
carotid.
920 Johnstone et al
AJP August 2009, Vol. 175, No. 2
of VSMC incorporating EDU in mouse carotids treated
with POVPC were significantly increased compared with
controls (10.73%  3.10%, Figure 5, B, D), but not in
PGPC treated carotids (0.06%  0.10%, Figure 5, B–D).
Changes in proliferation following application of lipids
were independent of macrophage recruitment to the site
of treatment (see supplemental Figure S4 at http://ajp.
amjpathol.org). These results show that POVPC, but not
PGPC, acts to specifically enhance the proliferation of
VSMC in vivo.
POVPC and PGPC Differentially Regulate Cx43
Expression, Phosphorylation, and Proliferation
in Vitro
We correlated in vivo observations with cultured ASMC by
measuring Cx43 expression and phosphorylation follow-
ing OxPL treatments. Under control conditions, ASMC
express detectable levels of Cx43-T, which were reduced
by treatments with POVPC, but not PGPC (Figure 6A).
Treatments with POVPC and PGPC enhanced the levels
of pS279/282 and pS368 respectively (Figure 6A). When
the ASMCs were treated with POVPC, there was a signif-
icant increase in cell proliferation (19.16%  2.05%)
compared with non-treated controls (1.73%  0.45%)
and PGPC treated cells (1.46%  0.27%, Figure 6B).
These results are strikingly similar to our observations
in vivo.
A summary of the in vivo and in vitro data for Cx43
following lipid applications is shown in supplemental Ta-
ble S1 at http://ajp.amjpathol.org.
Discussion
During atherogenesis, OxPL accumulation is thought to
modulate changes in VSMC,36,37 which occur concur-
rently with alterations in the expression of Cx43.1,38,39
The mechanisms for altered Cx43 expression in athero-
genesis have not been described, but may contribute
to disease progression. In this paper, we have de-
scribed for the first time that pro-atherosclerotic lipids
can specifically phosphorylate Cx43 at unique phos-
Figure 5. Cell proliferation in carotid VSMCs following POVPC and PGPC treatments. Qualitative ultrastructural analysis of representative carotids following
application of F127 Pluronic, POVPC, PGPC, and in ApoE/ mice demonstrates dividing VSMC nuclei in ApoE/ mice and POVPC-treated mice (A). Bars
represent 1 m and the asterisk highlights dividing nuclei (A). Representative images in (B) show EDU incorporation for: anesthetic control, F-127 pluronic gel,
POVPC, and PGPC treatments. Images in (C) are high magnifications of the EDU incorporation in VSMCs of carotids following POVPC treatment. The total nuclei
were compared with the number of nuclei incorporating EDU as a normalized percentage compared with F-127 control (D). In each image green represents nuclei,
red represents EDU, and arrows indicate areas of positive EDU incorporation. ***P  0.001.
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phorylation sites depending on the OxPL species, and
that these phosphorylation sites may contribute to
VSMC proliferation.
We first identified reductions in VSMC Cx43-T expres-
sion in ApoE/mice, consistent with studies by others in
western-diet, low-density lipoprotein-R/ atheroprone
mice.1 These mice were reported to form discrete aortic
atherosclerotic plaques and considered to be a good
model of early atherogenesis.40,41 Alterations in the ex-
pression and functionality of Cx43 can be controlled
by carboxyl terminus phosphorylation events, which
have not been previously described in atherogenesis. In
ApoE/ mice, we identified extensive Cx43 phosphory-
lation at both the pS279/282 and pS368 sites in carotid
VSMCs. These phosphorylation sites can be differentially
modulated through MAPK and PKC pathways respective-
ly,19 and may be important in the modulation of Cx43
expression and cell proliferation.18,42 It is therefore
plausible that phosphorylation at these sites are inte-
gral to changes in Cx43 expression and promotion of
atherogenesis.
Site-Specific Cx43 Phosphorylation Resulting
from OxPL Treatments
OxPAPC is composed of a number of structurally similar
lipid species, including PGPC and POVPC, which accu-
mulate at sites of atherosclerotic plaques.43 Previous
studies by our lab have demonstrated that the OxPAPC
mixture can have dramatic effects on connexin expres-
sion, phosphorylation, and function, however the effect of
individual OxPAPC species has not been demonstrat-
ed.20 To that end, carotids treated with POVPC demon-
strated enhanced Cx43 pS279/282, but reduced Cx43-T
expression, a result similar to that seen in ApoE/ mice.
However, POVPC treatments did not phosphorylate Cx43
at the S368 site, as was identified in the ApoE/ mice.
PGPC phosphorylated Cx43 at S368, but did not alter
levels of total Cx43 or pS279/282. The differences may be
explained by the biological activities of the phospho-
lipids, which act through MAPK (POVPC)- and PKC
(PGPC)-mediated pathways.11,14 This correlates with our
previous findings that OxPAPC enhanced Cx43 phos-
phorylation of the tyrosine 265 carboxyl terminus site
(pY265) in vivo and in vitro,20 which has been shown to be
activated through v-src pathways.19 It is therefore possi-
ble that POVPC acts to phosphorylate Cx43 S279/282,
which occurs primarily by MAPK and that PGPC targets
S368 phosphorylation through PKC pathways.4,7,19
One factor that is not accounted for by the phosphor-
ylation status alone is the reduction in total Cx43 expres-
sion in POVPC-treated mice (and cells). Expression of
Cx43 can be modulated by reduced synthesis,5 degrada-
tion before membrane targeting,44 or increased internaliza-
tion,45,46 all of which can be modulated by its phosphory-
lated status.47,48 Therefore specific phosphorylation at
pS279/282, but not pS368 (or pY26520), may be integral to
reduction or internalization of Cx43.
Treatments with POVPC, but not PGPC, reduced
Cx43-T in VSMCs, consistent with changes observed in
ApoE/ mice. This correlates with our previous studies
using OxPAPC, that not all OxPL isoforms alter total Cx43
expression.20 However, neither POVPC nor PGPC in-
duced changes in any of the other vascular connexins,
including Cx37, which is up-regulated in the ApoE/
mice. Increased Cx37 expression has been reported by
Burt et al to reduce the proliferative potential of rat insu-
loma cells, and may be another important aspect to
atherogenic control,49 with several lines of evidence sug-
gesting that in disease states Cx37 may act as a com-
pensatory mechanism for a more sustained loss of
Cx43.50–53 This concept correlates well with our findings
that Cx37 is only up-regulated in the ApoE/ mice. In
our studies acute treatments with the OxPLs excluded
any form of compensation by Cx37 or any of the other
connexins, which suggest the responses are specific to
alterations in Cx43.
Correlations between Altered Connexins and
Proliferative States in Atherogenesis
Qualitative ultrastructural analysis of ApoE/ mice dem-
onstrated that cells were in a proliferative state, which
correlates well with what is known about changes in the
phenotypic states of VSMC during atherogenesis. In-
creased proliferation was also identified by EDU incorpo-
ration in POVPC, but not PGPC treatments in vivo and in
vitro, which correlates with other in vitro studies demon-
strating POVPC can induce thymidine uptake in smooth
muscle cells.15,16 Because EDU (and other thymidine
Figure 6. Representative Western blot images
from ASMCs treated with either POVPC or
PGPC. Expression of Cx43-T, pS279/282 and
pS368 were determined and normalized for
loading with -tubulin (A). Black arrows in (A)
represent the Cx43 P0 band. Flow cytometric
analysis is shown of EDU incorporation in
ASMCs following treatments with POVPC, PGPC,
or PDGF as a positive proliferation marker (B).
The graph shows the percentage of cells incorpo-
rating EDU for each treatment, as compared with
negative controls. ***P  0.001.
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analogs) is taken up by the cell during the early part of
the cell cycle (transition from G1 to S phase), and our
time scale was on the order of 24 hours, our data
indicate that POVPC rapidly induces this cell cycle
transition. Because Cx43 is rapidly turned over in the
plasma membrane and has been highly associated
with proliferation, this appears to be a logical target for
cell-cycle initiation.
Treatments with POVPC enhanced VSMC proliferation,
which corresponded with reductions in Cx43 expression
and enhanced S279/282 phosphorylation. Studies by
others have demonstrated that a loss of Cx43,3,18,32–35 or
altered phosphorylation status,3,54 is sufficient to en-
hance the proliferative state. In addition to the many
studies suggesting Cx43 is capable of controlling cell
proliferation rates, several lines of evidence suggest that
pS279/282 may be critical in this regard. For example, in
PDGF-treated cells, proliferation is reduced by approxi-
mately 50% in cells transfected with Cx43-256M-trun-
cated mutant, as compared with controls,55 which sug-
gests that Cx43 carboxyl terminal sites between 256 and
382 are integral in proliferation control. Alanine substitu-
tions at the S279/282 sites (Cx43-S279A), preventing its
phosphorylation, caused slower growth rates in 3T3 fibro-
blasts and Neuro2a cells, as compared with controls and
other truncated mutants, further indicating this site is
important in normal cell growth.56 In clinical studies, mi-
totic cells in CIN III cervical lesions express high levels of
Cx43 pS279/282, which is reported to be integral to the
proliferation and differentiation states of cells in these
lesions.34 Phosphorylation of S279/282 is also required
for resumption of meiosis in arrested oocytes, without a
requirement for pS368.32 In ApoE/ mice the S279/282
and S368 sites are phosphorylated, in keeping with stud-
ies demonstrating these sites are capable of co-expres-
sion in Cx43,19 although this is not true of all phosphor-
ylation sites.57 The proliferation-associated activity of
pS279/282, but not pS368, does not necessarily impli-
cate a dominant function, but more likely differing roles or
interactions. Therefore pS279/282 of Cx43 may be an
important initiating factor in cellular proliferation or in
removal of the cell from quiescence. These previous
results, in keeping with our own findings, suggest that
sites in the carboxyl terminus are important in the alter-
ation of cellular proliferation. However, from our studies
we cannot rule out the participation of reductions in
Cx43-T in cellular proliferation.
Summary
We have identified that in the carotids of early athero-
genic mice, Cx43 is reduced and specifically phosphor-
ylated and that these changes can be effectively mim-
icked through applications of the OxPL species POVPC
and to a lesser extent PGPC. It is clear that more work is
required to elucidate the mechanisms involved between
Cx43 phosphorylation and proliferation, but we provide
here a definitive link between the two events.
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